- Details
- Andrea Miyahira hosts Tamara Lotan to discuss the paper, "Predicting Prostate Cancer Molecular Subtype with Deep Learning on Histopathologic Images." Dr. Lotan details the collaborative work with Angelo De Marzo's lab at Johns Hopkins and AIRA MATRIX, an AI deep learning company in India. The study aims to predict underlying molecular subtypes of prostate cancer using deep learning algorithms on h...
|
- Details
- In this discussion, Andrea Miyahira speaks with Ping Mu about his group's paper. The research focuses on the role of SYNCRIP in controlling APOBEC-driven mutagenesis in prostate cancer. Dr. Mu explains that the loss of SYNCRIP leads to a break in the mechanism controlling this mutagenesis driver, resulting in prostate cancer gaining resistance to AR therapy. The conversation highlights the tumor h...
|
- Details
- Neal Shore, Sarah Nielsen, and David Wise discuss broadening access to germline testing for prostate cancer patients. Reflecting on their collective efforts, including the PROCLAIM Trial and an editorial on Universal Genetic Germline Testing for Hereditary Cancer Syndromes, they emphasize democratizing genetic testing and universal accessibility. The conversation delves into the underutilization o...
|
- Details
- Federico Losco plays a key role in organizing UroTarget, a conference now in its seventh edition. UroTarget focuses on genitourinary tumors, bringing together a diverse group of professionals, including medical and radiation oncologists, pathologists, molecular biologists, and geneticists. The conference emphasizes open discussions based on real clinical cases, aiming to apply the latest uro-oncol...
|
- Details
- Burcu Darst explores her team's study on developing polygenic risk scores for prostate cancer in men of African and European ancestry. This study aims at addressing health disparities, and uses a large, diverse prostate cancer GWAS involving over 230,000 men from various populations. The results indicate that men in the top polygenic risk score decile are three to four times more likely to have pr...
|
- Details
- Zach Klaassen and Scott Eggener discuss the emotional toll of surgical complications, an issue seldom covered in textbooks. The discussion was sparked by Dr. Eggener's personal experience and subsequent New York Times article on the topic, which garnered global attention. The conversation explores the reality that surgeons face when complications occur, emphasizing the importance of self-care and...
|
- Details
- Andrew Hsieh highlights his team's research on a new tumor suppressor mechanism termed transcriptional-translational conflict. The research primarily focuses on ARID1A, a component of the SWI/SNF chromatin remodeling complex, which is frequently deregulated in bladder cancer. In absence of ARID1A, up-regulated oncogenic gene networks were observed, but no tumorigenesis occurred due to a conflict b...
|
- Details
- Andrea Miyahira interviews John Lee about his team's publication in Nature Communications. Dr. Lee discusses the focus of their research on a protein called STEAP1, known to be enriched in prostate cancers and the target of substantial therapeutic development. He provides an overview of previous efforts, such as Genentech's discontinued ADC, and ongoing developments like Amgen's AMG 509. The resea...
|
- Details
- Zach Klaassen speaks with Daniel Simmons about a community-led program designed to address prostate cancer detection and education in Albany's rural region. Dr. Simmons reveals that the initiative emerged from a conversation with Morehouse School of Medicine about early detection of prostate cancer. The community constructed the project, drawing together faith-based communities, hospitals, barbers...
|
- Details
- Christina Curtis shares insights from her work on breast and gastrointestinal cancers, discussing their potential application to prostate cancer. The focus of her discussion revolves around innovative strategies for defining biomarkers of therapy response using spatial proteomic approaches. Dr. Curtis describes how this new technology lets researchers examine the composition of tumor cells and the...
|
